![Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial. - Abstract - Europe PMC Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6439800/bin/jamafacialplastsurg-21-125-g002.jpg)
Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial. - Abstract - Europe PMC
![These highlights do not include all the information needed to use TAZAROTENE GEL safely and effectively. See full prescribing information for TAZAROTENE GEL. TAZAROTENE gel, 0.05% and 0.1%, for topical use Initial These highlights do not include all the information needed to use TAZAROTENE GEL safely and effectively. See full prescribing information for TAZAROTENE GEL. TAZAROTENE gel, 0.05% and 0.1%, for topical use Initial](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=tazarotene-gel-01-carton-100g.jpg&id=721682)
These highlights do not include all the information needed to use TAZAROTENE GEL safely and effectively. See full prescribing information for TAZAROTENE GEL. TAZAROTENE gel, 0.05% and 0.1%, for topical use Initial
![Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity | Business Wire Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity | Business Wire](https://mms.businesswire.com/media/20220920005512/en/1576844/5/Tazarotene_Gel_PR_Approved.jpg)